<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045053</url>
  </required_header>
  <id_info>
    <org_study_id>Hamaky17</org_study_id>
    <nct_id>NCT05045053</nct_id>
  </id_info>
  <brief_title>Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking</brief_title>
  <official_title>Efficacy of Xiidra in the Management Dry Eye Disease After Corneal Collagen Cross Linking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      dry eye disease after corneal collagen cross linking affect ocular function leading to&#xD;
      reduced vision, photophobia, glare, halos, and foreign body sensation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      first group of patients were treated with 0.5 % xiidra twice daily and artificial tears for 6&#xD;
      months.Second group treated with artificial tears for 6 months. the treatment starts after&#xD;
      corneal collagen cross linking in both groups ,Baseline and post-treatment full ophthalmic&#xD;
      examination was done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>computer based masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Break up Time</measure>
    <time_frame>6 months</time_frame>
    <description>fluorescein sodium stripes will be used for measurement of Break up Time in seconds at baseline and during the study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Corneal Disease</condition>
  <arm_group>
    <arm_group_label>xiidra group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients are treated with 0.5 % xiidra twice daily and artificial tears for 6 months after corneal collagen cross linking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patient are treated with artificial tears for 6 months after corneal collagen cross linking in both groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiidra 5% Ophthalmic Solution</intervention_name>
    <description>lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking</description>
    <arm_group_label>xiidra group</arm_group_label>
    <other_name>lifitegrast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  corneal collagen cross linking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  systemic or ocular diseases ,previous ocular surgery, corneal pathology and contact&#xD;
             lens wearers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Elhamaky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha university faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tarek R Elhamaky, M.D.</last_name>
    <phone>+971 503207889</phone>
    <email>dr_thamakyy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tarek Elhamaky</last_name>
    <phone>+971 503207889</phone>
    <email>dr_thamakyy@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>INMC</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>46266</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TAREK R ELHAMAKY, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Tarek Roshdy mohamed Mahgoub ELhamaky</investigator_full_name>
    <investigator_title>assisatant professor</investigator_title>
  </responsible_party>
  <keyword>dry eye</keyword>
  <keyword>cross linking</keyword>
  <keyword>xiidra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lifitegrast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

